MicroRNA-208a is a cardiac specific oligo-nucleotide. We aimed at investigating the ability of microRNA-208a to diagnose myocardial infarction and predict the outcome of primary percutaneuos coronary angiography (PCI). Patients (n = 75) presented by chest pain were recruited into two groups. Group 1 (n = 40) had ST elevation myocardial infarction (STEMI) and underwent primary PCI: 21 patients had sufficient reperfusion and 19 had no-reflow. Group 2 (n = 35) had negative cardiac troponins (cTns). Plasma microRNA-208a expression was assessed using quantitative polymerase chain reaction and patients were followed for occurrence of in-hospital major adverse cardiac events (MACE). MicroRNA-208a could diagnose of MI (AUC of 0.926). After primary PCI, it was superior to cTnT in prediction of no-reflow (AUC difference of 0.231, P = 0.0233) and MACE (AUC difference of 0.367, P = 0.0053). Accordingly, circulating levels of miR-208a can be used as a diagnostic marker of MI and a predictor of no-reflow and in-hospital MACE.

Receiver operating curve analysis of no-reflow prediction of miRNA208a, CK-MB and hs-Troponin T. MicroRNA-208a shows significantly higher prediction of no-reflow as compared to routine cardiac biomarkers.

MicroRNA-208a 是一种心脏特异性寡核苷酸。我们的目的是研究 microRNA-208a 诊断心肌梗死和预测初次经皮冠状动脉造影 (PCI) 结果的能力。将出现胸痛的患者 ( n = 75) 分为两组。第 1 组（ n = 40）患有 ST 段抬高型心肌梗死 (STEMI)，并接受了直接 PCI：21 名患者获得充分再灌注，19 名患者未出现复流。第 2 组 ( n = 35) 心肌肌钙蛋白 (cTns) 呈阴性。使用定量聚合酶链反应评估血浆 microRNA-208a 表达，并跟踪患者院内主要不良心脏事件 (MACE) 的发生情况。 MicroRNA-208a 可以诊断 MI（AUC 为 0.926）。初次PCI后，它在预测无复流（AUC差异为0.231， P = 0.0233）和MACE（AUC差异为0.367， P = 0.0053）方面优于cTnT。因此，miR-208a 的循环水平可用作 MI 的诊断标志物以及无复流和院内 MACE 的预测因子。

miRNA208a、CK-MB 和 hs-肌钙蛋白 T 的无复流预测的受试者工作曲线分析。与常规心脏生物标志物相比，MicroRNA-208a 显示出显着更高的无复流预测。